Somatal mutations in MDS and response to therapy
AZA indicates 5-azacitidine; DAC, decitabine; Len, lenalidomide; MDS, myelodysplastic syndrome; ATRA, all-trans retinoic acid; ATG, antithymocyte globulin; VPA, valproic acid; EPO, erythropoietin; G, neupogen/G-CSF; MPN, myeloproliferative neoplasm; NGS, next generation sequencing; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenias with multilineage dysplasia; 5q−, 5q minus syndrome; RAEB1, refractory anemia with excess blasts 1; RAEB2, refractory anemia with excess blasts 2; RAEB-t, refractory anemia with excess blasts in transformation; MDS-U, myelodysplatsic syndrome unclassified; RARS-T, refractory anemia with ringed sideroblasts with thrombocytosis; RCMD-RS, refractory cytopenias with multilineage dysplasia and ringed sideroblasts; AML, acute myelogenous leukemia; sAML, secondary AML; tAML, therapy-related AML; tMDS, therapy-related MDS; CMML, chronic myelomonocytic leukemia; PMF, primary myelofibrosis; VAF, variant allele frequency; CR, complete response; NR, no response; PR, partial response; PFS, progression-free survival; OS, overall survival; EFS, event-free survival; LFS, leukemia free survival; OR, odds ratio; ORR, overall response rate; mut, mutation; and WT, wild-type.
